Abstract AIMS/HYPOTHESIS The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the α3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling […]
Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
January 1, 2017
Diabetologia